Efficacy and safety analysis of chemotherapy combined with inetetamab and pyrotinib versus capecitabine combined with pyrotinib in second-line treatment for HER2 positive metastatic breast cancer
10.3760/cma.j.cn115807-20240914-00293
- VernacularTitle:化疗联合伊尼妥单抗和吡咯替尼对比卡培他滨联合吡咯替尼在HER2阳性转移性乳腺癌二线治疗的疗效及安全性分析
- Author:
Minjing YOU
1
;
Jian LIU
1
;
Mulan CHEN
1
;
Nani LI
1
;
Fan WU
1
Author Information
1. 福建医科大学肿瘤临床医学院 福建省肿瘤医院肿瘤内科，福州 350014
- Publication Type:Journal Article
- Keywords:
HER2 positive metastatic breast cancer;
Second-line therapy;
Inetetamab;
Pyrotinib;
Capecitabine
- From:
Chinese Journal of Endocrine Surgery
2024;18(6):846-852
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the efficacy and safety of chemotherapy combined with inetetamab and pyrotinib (triplet therapy group), and capecitabine combined with pyrotinib (doublet therapy group) in second-line treatment for HER2-positive metastatic breast cancer patients who have failed on trastuzumab.Methods:A retrospective analysis was conducted on 30 HER2-positive metastatic breast cancer patients who underwent second-line treatment with a regimen of chemotherapy plus inetetamab and pyrotinib at Fujian Provincial Tumor Hospital between Jan. 1, 2020 and Dec. 31, 2023, and on 28 HER2-positive metastatic breast cancer patients treated with capecitabine plus pyrotinib during the same period. The study analyzed the differences in ORR (objective response rate), CBR (clinical benefit rate), PFS (progression free survival), and OS (overall survival) between the two groups and documented any adverse reactions observed during treatment.Results:The three-drug group exhibited a higher ORR rate than the two-drug group (60.0% vs. 39.2%, P>0.05), and a higher CBR rate (83.3% vs. 57.1%, P<0.05). Univariate analysis and multivariate Logistic regression analysis showed that group (three drug group compared to two drug group) was the only independent prognostic factor affecting median PFS in patients ( P<0.05). The median PFS of the three drug group was higher than that of the two drug group (19 months vs. 11 months, P<0.05), but by the end of follow-up, neither group had reached the median OS ( P>0.05) .The three-drug group and the two-drug group demonstrated 1-year OS rates of 85% and 85%, 2-year OS rates of 74% and 63%, and 3-year OS rates of 56% and 52%, respectively. The most frequent hematological toxicities in the three-drug group were leukopenia, neutropenia, and anemia, with diarrhea being the most common non-hematological toxicity. No significant differences were observed in adverse reaction profiles between the two groups ( P>0.05) . Conclusion:In the second-line treatment of HER2 positive metastatic breast cancer, chemotherapy + inetetamab + pyrotinib significantly prolonged the median PFS and increased the CBR compared with the current domestic standard capecitabine + pyrotinib regimen, and did not increase the incidence of adverse reactions, demonstrating higher efficacy and safety.
